The systemic inflammatory burst in heart failure patients (EF ≤30%) undergoing cardiac surgery: A new therapeutic target?

2012 ◽  
Vol 60 (S 01) ◽  
Author(s):  
N Monsefi ◽  
A Geyer ◽  
A Moritz ◽  
A Zierer
Keyword(s):  
Heart Failure ◽  
Cardiac Surgery ◽  
Therapeutic Target ◽  
Heart Failure Patients

scholarly journals Platelet aggregometry cannot identify uremic platelet dysfunction in heart failure patients prior to cardiac surgery

2016 ◽  
Vol 31 (5) ◽  
pp. e22084
Author(s):  
Josh Showalter ◽  
Nghia D. Nguyen ◽  
Samer Baba ◽  
Chi Hyun Lee ◽  
Jing Ning ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Surgery ◽  
Platelet Dysfunction ◽  
Heart Failure Patients ◽  
Platelet Aggregometry

Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases

2014 ◽  
Vol 92 (7) ◽  
pp. 558-565 ◽  
Author(s):  
Nirmal Parajuli ◽  
Tharmarajan Ramprasath ◽  
Vaibhav B. Patel ◽  
Wang Wang ◽  
Brendan Putko ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Diseases ◽  
Angiotensin Converting Enzyme ◽  
Therapeutic Target ◽  
Ang Ii ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2 ◽  
Heart Failure Patients ◽  
Positive Effects ◽  
Mas Receptor

Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase that metabolizes several vasoactive peptides, including angiotensin II (Ang-II; a vasoconstrictive/proliferative peptide), which it converts to Ang-(1–7). Ang-(1–7) acts through the Mas receptor to mediate vasodilatory/antiproliferative actions. The renin–angiotensin system involving the ACE–Ang-II–Ang-II type-1 receptor (AT1R) axis is antagonized by the ACE2–Ang-(1–7)–Mas receptor axis. Loss of ACE2 enhances adverse remodeling and susceptibility to pressure and volume overload. Human recombinant ACE2 may act to suppress myocardial hypertrophy, fibrosis, inflammation, and diastolic dysfunction in heart failure patients. The ACE2–Ang-(1–7)–Mas axis may present a new therapeutic target for the treatment of heart failure patients. This review is mainly focused on the analysis of ACE2, including its influence and potentially positive effects, as well as the potential use of human recombinant ACE2 as a novel therapy for the treatment cardiovascular diseases, such as hypertension and heart failure.

scholarly journals A risk score for predicting 30-day mortality in heart failure patients undergoing non-cardiac surgery

2014 ◽  
Vol 16 (12) ◽  
pp. 1310-1316 ◽  
Author(s):  
Charlotte Andersson ◽  
Gunnar H. Gislason ◽  
Mark A. Hlatky ◽  
Kathrine Bach Søndergaard ◽  
Jannik Pallisgaard ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Surgery ◽  
Risk Score ◽  
Heart Failure Patients

Efficacy of Prophylactic Intra-Aortic Balloon Pump Therapy in Chronic Heart Failure Patients Undergoing Cardiac Surgery

2014 ◽  
Vol 38 (11) ◽  
pp. 967-972 ◽  
Author(s):  
Yalin Yildirim ◽  
Simon Pecha ◽  
Mathias Kubik ◽  
Yousuf Alassar ◽  
Tobias Deuse ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiac Surgery ◽  
Chronic Heart Failure ◽  
Pump Therapy ◽  
Heart Failure Patients ◽  
Intra Aortic Balloon Pump

CHRONIC KIDNEY DISEASE IN HEART FAILURE PATIENTS UNDERGOING NON-CARDIAC SURGERY

2020 ◽  
Vol 75 (11) ◽  
pp. 1021
Author(s):  
Boyangzi Li ◽  
Tanya Wilcox ◽  
Nathaniel Rosso Smilowitz ◽  
Jonathan Newman ◽  
Jeffrey Berger
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Cardiac Surgery ◽  
Kidney Disease ◽  
Heart Failure Patients
Sign in / Sign up

Export Citation Format

Share Document